By sakshimore 
Date of Publication: 2025-Jul-15
Roots Analysis has published its latest report titled ‘Biosimilars Market’, which offers a detailed assessment of the global market and its regional components. This report outlines current performance indicators, estimates future growth, and provides a long-term outlook from 2025 to 2035. It presents an overview of how the market size has evolved in recent years and offers insights into future developments based on available data.
The global biosimilars market is estimated to grow from $24.2 billion in 2024 to $130.1 billion by 2035, at a CAGR of 16.5% during the forecast period, till 2035.. While outlining historical trends and future projections, the report maintains a neutral approach, avoiding speculation. It highlights overall shifts in market structure, demand, and product availability across different regions.
The study focuses on multiple aspects of the market including development strategies, financial performance, and competitive positioning. It includes detailed profiles of leading participants, allowing readers to better understand the competitive scenario. The analysis of top companies in Biosimilars includes their offerings, strategies, and business footprint. These profiles help contextualize the broader landscape of the Biosimilars Market .
Drug Class
- Monoclonal Antibodies
- Proteins
- Peptides
- Others
Therapeutic Area
- Oncological Disorders
- Autoimmune and Inflammatory Disorders
- Hematological Disorders
- Metabolic Disorders
- Other Disorders
Type of Manufacturer
- Contract Manufacturers
- In-house Developers
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Geographical Regions
- North America (US and Canada)
- Europe (Germany, UK, France, Spain, Italy, Switzerland, Belgium,Denmark and Rest of the Europe)
- Asia-Pacific (China, India, Japan, South Korea and Australia)
- Middle East and North Africa (Saudi Arabia, Egypt and UAE)
- Latin America (Brazil, Mexico and Argentina)
Key Companies Profiled
- Amgen Inc
- BIOCAD
- Biocon
- Celltrion
- Coherus BioSciences
- Dr. Reddy’s Laboratories
- Eli Lilly
- Fresenius Kabi
- Intas Pharmaceuticals
- Pfizer Inc
- Sandoz
- STADA
- Teva Pharmaceutical
Reference: https://www.rootsanalysis.com/reports/biosimilars-market.html
The report provides detailed information on important market parameters including Biosimilars Market share across regions and segments. It examines broad factors that may influence overall performance. Attention has been given to the general framework within which companies operate, including regulatory policies and standard market practices. The market forecast section provides an outline of projected shifts and estimated performance across the next decade.
The analysis also examines marketing initiatives and operational strategies adopted by industry participants. This includes common business approaches such as joint ventures, regional expansions, and mergers. The content remains factual, supporting conclusions with relevant data and historical references. The structure is designed to ensure the information is accessible and reusable for a wide range of industry stakeholders.
Another section focuses on the global availability of products and services within the market for Biosimilars . It outlines general supply chain trends and availability across end-use sectors. Factors such as pricing structures, logistics, and procurement channels are mentioned to offer a complete understanding of the market environment.
Research Methodology
This report is based on structured data collection using both primary and secondary sources. Analysts gathered input from public reports, company statements, and expert consultations. The resulting insights were reviewed and validated for accuracy. The methodology supports transparency and ensures that the findings presented are reliable for use by decision-makers and businesses operating in the Biosimilars industry.
We appreciate your interest in our report. For questions, additional data points, or a custom version of this research tailored to your business needs, please contact our team at sales@rootsanalysis.com. We are available to help you access the specific insights you are looking for.
The new research study consists of market trends, detailed market analysis, competitive landscape and market forecast and opportunity analysis. The biosimilars market growth over the next decade is expected to be driven by increased biologics patent expiry, leading to the development of alternative biosimilars that are clinically similar to their reference biologics.
In recent years, the biologics market has witnessed robust expansion, which is primarily due to its enhanced effectiveness in treating chronic disorders. However, the high costs associated with biologics pose significant economic and healthcare burden. As demand for biologics continues to rise, the developers are seeking novel strategies to maximize returns on investment and the need for more affordable alternative biological products, with similar safety and efficacy profiles. Amidst patent cliffs, shrinking drug pipelines, and pressure to reduce treatment costs, biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry.
In the past few years, the domain has witnessed increased investment and collaborative efforts by the biosimilar developers. Further, regulatory advancements, streamlined approval procedures, and interchangeability studies have supported the biosimilars development. As the demand for biosimilars continues to rise as an economical choice, the in-house development and outsourcing services operations is expected to increase correspondingly. This trend is poised to present attractive growth opportunities for biosimilar developers.
About Roots Analysis
Who Are They
- Roots Analysis is a globally recognized provider of market intelligence, competitive research, and consulting services.
- With 12+ years of experience, the company has worked with 750+ clients across the globe — including Fortune 500 companies, emerging start-ups, academic institutions, and strategic investors.
- Backed by a network of 450,000+ senior professionals, Roots Analysis delivers data-driven insights that guide business-critical decisions.
- The firm serves a diverse set of high-impact industries, including Life Sciences, Semiconductors & Electronics, Chemicals & Materials, and Information & Communication Technology (ICT), making them a trusted partner across innovation-driven sectors.
- The firm is known for quality of their research, completeness and depth of the research. The team is actively working with numerous global clients to support key decision-makers, smart insights for revenue impact decisions, strategic growth.
What They Do
- Roots Analysis helps organizations understand and respond to evolving markets and emerging technologies.
- They offer data-backed insights that support informed decision-making and long-term strategy development.
- Their team continuously monitors innovation and disruption across high-impact sectors, identifying growth opportunities early on.
What They Offer
- Syndicated Market Reports – Structured, in-depth reports covering niche and fast-evolving markets.
- Custom Research & Consulting – Bespoke studies designed to align with specific business goals and challenges.
- Competitive Intelligence Solutions – Deep market mapping, pipeline analysis, partnership tracking, and investor profiling.
What Sets Them Apart
- Sector Expertise – Especially strong in pharmaceuticals, biotechnology, healthcare, and deep tech.
- Analytical Strength – Research is grounded in robust methodologies, real-world data, and strategic foresight.
- Client-Centric Approach – Every engagement is tailored, no generic solutions.
- Global Credibility – Trusted by decision-makers and thought leaders around the world.
- Forward-Looking Vision – Roots Analysis focuses not just on where markets are, but where they’re heading.
Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
